Monsanto and Novozymes Team Up to Provide Sustainable Bioagricultural Solutions

  Monsanto and Novozymes Team Up to Provide Sustainable Bioagricultural
  Solutions

   The companies establish The BioAg Alliance to discover, develop and sell
microbial solutions that enable farmers worldwide to increase crop yields with
                                  less input

Business Wire

ST. LOUIS & COPENHAGEN, Denmark -- December 10, 2013

Monsanto Company (NYSE: MON) and Novozymes (NASDAQ OMX: NZYM B) today announce
a long-term strategic alliance to transform research and commercialization of
sustainable microbial products that will provide a new platform of solutions
for growers around the world. The BioAg Alliance will allow the companies to
leverage employees, technologies and commercial assets in the companies’
agricultural biologicals portfolios. The BioAg Alliance is unique in the
industry, bringing together Novozymes’ commercial BioAg operations and
capabilities within microbial discovery, development and production with
Monsanto’s microbial discovery, advanced biology, field testing and commercial
capabilities. The result will be a comprehensive research, development and
commercial collaboration to help farmers globally meet the challenge of
producing more with less in a sustainable way – for the benefit of
agriculture, consumers, the environment and society at large.

“As the world population grows at tremendous pace over the next decades, we
need to significantly increase the output from our land without increasing the
pressure on the environment,” says Peder Holk Nielsen, CEO of Novozymes.
“Today, we forge a game-changing alliance with the potential to transform
global agriculture. The combined capabilities of Novozymes and Monsanto create
an innovation powerhouse with a unique opportunity and approach to unleash the
transformational opportunity in naturally derived microbial solutions in
agriculture.”

“Monsanto, Novozymes and the farmer customers we serve share a need to meet
growing demand in a sustainable way, and investing in the research and
development of agricultural biological technologies like microbials is another
step in that direction and a natural extension of our core business,” says
Robb Fraley, Ph.D., Chief Technology Officer of Monsanto. “Just as Monsanto
has done with leadership investments in our precision agriculture platform, we
see this collaboration as being the same type of catalyst for taking our
biologicals work from a technology to a full-fledged platform that represents
the next layer of opportunity for growers to drive yield and productivity
while helping the preservation of finite natural resources in our precious
planet.”

Sustainable Biological Solutions in Agriculture

Microbial solutions are a significant part of the agricultural biologicals
industry, which today represents roughly $2.3 billion in annual sales and has
posted mid-teens sales growth each of the last several years. Microbial-based
solutions are derived from various naturally-occurring microorganisms such as
bacteria and fungi. They can protect crops from pests and diseases and enhance
plant productivity and fertility. With faster development cycles compared to
other agricultural innovations, as well as broad geographic and crop
applicability, microbial solutions offer tremendous potential to deliver
sustainable, cost-effective solutions that can increase yield using less
input.

The emerging agricultural biological technologies complement the integrated
systems approach that is necessary in modern agriculture, bringing together
breeding, biotechnology and agronomic practices to improve and protect crop
yields.

The BioAg Alliance

Novozymes has over the last decade leveraged its know-how and experience in
industrial enzymes and microbial technologies to build global positions in the
agricultural biologicals market with a broad and proven product portfolio and
annual revenue of approximately $120 million in 2012. Combining its strengths
within microbial discovery, application development and fermentation and its
leadership position in the agricultural biologicals market, Novozymes brings
an established and unique starting point for the alliance to accelerate from
in both the short and long term.

Monsanto has a research team working on microbial solutions and has one of the
most extensive seeds and traits discovery, field-testing and commercial
footprints in the industry. All this will help accelerate microbial
development through the alliance, enabling more farmers to get more solutions,
faster. Last year the company introduced its agricultural biologicals platform
and earlier this year acquired the assets of the agricultural company Agradis
Inc. as it builds out its discovery capabilities in the microbial space.

In bringing together Novozymes’ and Monsanto’s capabilities, the companies are
poised to deliver an entirely new category of more effective microbial
solutions for global broad-acre crops, fruit and vegetables. Under the
collaboration:

  *Monsanto and Novozymes will maintain independent and complementary
    internal and external discovery research programs to identify microbial
    targets with the potential to help farmers.
  *Novozymes will be responsible for production and supply of the microbial
    solutions to Monsanto, building on its expertise within fermentation.
    Monsanto will serve as the lead for field testing, registration and
    commercialization of all alliance products.
  *The companies will co-manage the alliance and co-fund research and
    development efforts.
  *Monsanto will pay Novozymes an aggregate upfront payment of $300 million
    net in recognition of Novozymes’ ongoing business and microbial
    capabilities, and for Novozymes to supply alliance products.
  *Marketing responsibility for Novozymes’ current product portfolio in
    agricultural biologicals will be transferred to Monsanto along with much
    of the Novozymes commercial organization currently responsible for that
    work. The two companies will work to ensure that existing customer
    relationships and know-how are maintained and further built on for short-
    and long-term success.
  *Both companies will benefit from profits on commercialized products
    resulting from this alliance and those products brought into the alliance
    by the parties. Through the alliance, the companies will also test and
    sell commercial microbial products purchased from other suppliers to bring
    additional value to farmers.

The agreement is subject to the approval of the relevant national antitrust
authorities to the extent required. The alliance is expected to close in early
2014. Further terms of the alliance were not disclosed.

In conjunction with this announcement, Novozymes and Monsanto will hold a
joint conference call for investors. The call is scheduled for 10 a.m. EST
today, Tuesday, December 10, 2013. Presentation slides and a simultaneous
audio webcast of the conference call may be accessed by visiting the
companies’ websites at www.monsanto.com/investors or
www.novozymes.com/en/investor/Pages/default.aspx. Visitors may need to
download Windows Media Player™ prior to listening to the webcast. Following
the live broadcast, a replay of the webcast will be available on the
companies’ websites.

About Novozymes

Novozymes is the world leader in bioinnovation. Together with customers across
a broad array of industries Novozymes creates tomorrow’s industrial
biosolutions, improving its customers' business and the use of our planet's
resources. With over 700 products used in 130 countries, Novozymes’
bioinnovations increase industrial performance and safeguard the world’s
resources by offering superior and sustainable solutions for tomorrow’s
ever-changing marketplace. Read more at www.novozymes.com.

About Monsanto Company

Monsanto Company is a leading global provider of technology-based solutions
and agricultural products that improve farm productivity and food quality.
Monsanto remains focused on enabling both small-holder and large-scale farmers
to produce more from their land while conserving more of our world's natural
resources such as water and energy. To learn more about our business and our
commitments, please visit: www.monsanto.com. Follow our business on Twitter^®
at www.twitter.com/MonsantoCo, on the company blog, Beyond the Rows^® at
www.monsantoblog.com, or subscribe to our News Release RSS Feed.

Novozymes’ Cautionary Statements Regarding Forward-Looking Information:

This company announcement contains forward-looking statements. Forward-looking
statements are, by their very nature, associated with risks and uncertainties
that may cause actual results to differ materially from expectations. The
uncertainties may include unexpected developments in the international
currency exchange and securities markets, market-driven price decreases for
Novozymes’ products, and the launch of competing products in Novozymes’ core
areas.

Monsanto Cautionary Statements Regarding Forward-Looking Information:

Certain statements about Monsanto contained in this release are
"forward-looking statements," such as statements concerning the company’s
anticipated financial results, current and future product performance,
regulatory approvals, business and financial plans and other non-historical
facts. These statements are based on current expectations and currently
available information. However, since these statements are based on factors
that involve risks and uncertainties, the company's actual performance and
results may differ materially from those described or implied by such
forward-looking statements. Factors that could cause or contribute to such
differences include, among others: continued competition in seeds, traits and
agricultural chemicals; the company's exposure to various contingencies,
including those related to intellectual property protection, regulatory
compliance and the speed with which approvals are received, and public
acceptance of biotechnology products; the success of the company's research
and development activities; the outcomes of major lawsuits and the
previously-announced SEC investigation; developments related to foreign
currencies and economies; successful operation of recent acquisitions;
fluctuations in commodity prices; compliance with regulations affecting our
manufacturing; the accuracy of the company's estimates related to distribution
inventory levels; the company's ability to fund its short-term financing needs
and to obtain payment for the products that it sells; the effect of weather
conditions, natural disasters and accidents on the agriculture business or the
company's facilities; and other risks and factors detailed in the company's
most recent Form 10-K Report to the SEC. Undue reliance should not be placed
on these forward-looking statements, which are current only as of the date of
this release. The company disclaims any current intention or obligation to
update any forward-looking statements or any of the factors that may affect
actual results.

Photos/Multimedia Gallery Available:
http://www.businesswire.com/multimedia/home/20131210005834/en/

Multimedia
Available:http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50765938&lang=en

Contact:

Analysts and Investors:
Monsanto
Bryan Hurley, +1-314-694-8148
or
Novozymes
Thomas Bomhoff, +45 30771226
or
Media:
Monsanto
Sara Miller, +1-314-694-5824
or
Novozymes
Frederik Bjørndal, +45 30770236
 
Press spacebar to pause and continue. Press esc to stop.